Loss of runt‐related transcription factor 3 induces gemcitabine resistance in pancreatic cancer
暂无分享,去创建一个
Kazuhide Yamamoto | Takehiro Tanaka | Shigeru Horiguchi | Koichi Ichimura | K. Ichimura | H. Shiraha | Shin-ichi Nishina | M. Matsubara | S. Horiguchi | M. Iwamuro | A. Takaki | K. Nouso | T. Yagi | Kazuhide Yamamoto | Masaya Iwamuro | Takehiro Tanaka | Kazuhiro Nouso | Takahito Yagi | Hidenori Shiraha | Teruya Nagahara | Jyunnro Kataoka | Minoru Matsubara | Shinichi Nishina | Hironari Kato | Akinobu Takaki | H. Kato | T. Nagahara | Jyun Kataoka | Hironari Kato | Teruya Nagahara
[1] G. Peters,et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines , 2003, British Journal of Cancer.
[2] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[3] Jörg König,et al. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma , 2005, International journal of cancer.
[4] P. Catalano,et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Dong Tang,et al. Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer. , 2011, Oncology reports.
[6] K. Chayama,et al. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. , 2008, International journal of oncology.
[7] H. Takeuchi,et al. Prognostic significance of the immunohistochemical expression of O6‐methylguanine‐DNA methyltransferase, P‐glycoprotein, and multidrug resistance protein‐1 in glioblastomas , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.
[8] Yoshiaki Ito,et al. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors , 2010, Oncogene.
[9] N. Lemoine,et al. Pancreatic Cancer Genetics , 2001, Pancreatology.
[10] R. Hruban,et al. An Introduction to Pancreatic Adenocarcinoma Genetics, Pathology and Therapy , 2002, Cancer biology & therapy.
[11] Manuel Salto-Tellez,et al. Molecular pathology of RUNX3 in human carcinogenesis. , 2009, Biochimica et biophysica acta.
[12] S. Itohara,et al. Causal Relationship between the Loss of RUNX3 Expression and Gastric Cancer , 2002, Cell.
[13] Scott E Kern,et al. Focus on pancreas cancer. , 2002, Cancer cell.
[14] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[15] S. Bae,et al. Tumor suppressor activity of RUNX3 , 2004, Oncogene.
[16] H. Sugimoto,et al. Adverse prognosis of epigenetic inactivation in RUNX3 gene at 1p36 in human pancreatic cancer , 2008, British Journal of Cancer.
[17] R. Ueda,et al. The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity , 2006, Molecular Cancer Therapeutics.
[18] C. Sakakura,et al. Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines , 2003, Oncogene.
[19] Lijun Sun,et al. Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl‐2, MDR‐1 and MRP‐1 , 2005, International journal of cancer.
[20] M. Mimeault,et al. Recent Advances on the Molecular Mechanisms Involved in Pancreatic Cancer Progression and Therapies , 2005, Pancreas.
[21] H. Friess,et al. RUNX3 expression in primary and metastatic pancreatic cancer , 2004, Journal of Clinical Pathology.
[22] Kosei Ito. RUNX3 in oncogenic and anti‐oncogenic signaling in gastrointestinal cancers , 2011, Journal of cellular biochemistry.
[23] Donghui Li,et al. Association of multi‐drug resistance gene polymorphisms with pancreatic cancer outcome , 2011, Cancer.
[24] H. Ueno,et al. Phase I trial of gemcitabine in patients with advanced pancreatic cancer. , 2001, Japanese journal of clinical oncology.
[25] E. Giovannetti,et al. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer , 2006, Molecular Cancer Therapeutics.
[26] H. Kocher,et al. Pancreatic Cancer , 2019, Methods in Molecular Biology.
[27] Y. Nakanishi,et al. Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis , 2011, BMC Cancer.
[28] Huamin Wang,et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. , 2009, Cancer research.
[29] Jing Wen,et al. CD44‐positive cells are responsible for gemcitabine resistance in pancreatic cancer cells , 2009, International journal of cancer.
[30] W. Hagmann,et al. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. , 2010, Neoplasia.
[31] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[33] R. Langer,et al. High pretherapeutic thymidylate synthetase and MRP‐1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients , 2010, Journal of surgical oncology.
[34] A. Rzhetsky,et al. The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.
[35] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[36] R. Jesenofsky,et al. ATP-Binding Cassette C Transporters in Human Pancreatic Carcinoma Cell Lines , 2008, Pancreatology.
[37] K. Faber,et al. Expression of Multidrug Resistance–Associated Proteins Predicts Prognosis in Childhood and Adult Acute Lymphoblastic Leukemia , 2005, Clinical Cancer Research.
[38] D. V. Von Hoff,et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.